

National Stock Exchange Of India Limited**Department : INVESTIGATION**

Download Ref No: NSE/INVG/ 42001

Date : August 29, 2019

Circular Ref No: 294/2019

To All NSE Members,

Sub: SEBI Order in the matter of Transgene Biotek Limited

This is with reference to NSE Circular No. NSE/INVG/28109 dated November 20, 2014 in respect of SEBI order no. WTM/RKA/ISD/136/2014 dated November 20, 2014 and NSE Circular No. NSE/INVG/31945 dated March 10, 2016 in respect of SEBI order no. WTM/RKA/ISD/30 /2016 dated March 09, 2016 respectively, had restrained various Entities from accessing the securities market and further prohibited them from buying, selling or dealing in securities in any manner whatsoever, till further directions.

SEBI, now vide its Order no. WTM/AB/EFD-1/DRA-4/18/2019-20 dated August 28, 2019 has inter-alia issued the following directions:

Transgene Biotek Limited (AABCT3840P) shall continue to be restrained from accessing the securities market and be further prohibited from buying, selling or otherwise dealing in securities (including units of mutual funds), directly or indirectly, or being associated with the securities market in any manner, whatsoever, till compliance with direction contained in para 49 (a) of the order and thereafter for an additional period of two years from the date of bringing back the money as directed in para 49 (a) of the order. During the period of restraint, the existing holding of securities (including units of mutual funds) shall also remain frozen.

Mr. K. Koteswara Rao (AHOPK5487E), Mr. Soma Sekhar Marthi (ACAPM9616N) and Mr. Narayana Murthy Pentyala (ANBPP4186A) shall continue to be restrained from accessing the securities market and further prohibited from buying, selling or otherwise dealing in securities (including units of mutual funds), directly or indirectly, or being associated with the securities market in any manner, whatsoever, for a period of five years from the date of the interim order passed in the matter. During the period of restraint, the existing holding of securities (including units of mutual funds) of these Entities shall also remain frozen.

Sristek Consulting Pvt. Ltd. (now known as Sristek Clinical Research Solutions Limited) (PAN not provided), Mr. Deepak Mishra (PAN not provided) and Mr. Sampath Kumar Meesala (AIIPM9512D) re hereby restrained from accessing the securities market and further prohibited from buying, selling or otherwise dealing in securities (including units of mutual funds), directly or indirectly, or being associated with the securities market in any manner, whatsoever, for a period of three years from the date of this order. During the period of restraint, the existing holding of securities (including units of mutual funds) of these Entities shall also remain frozen.

This Order shall come into force with immediate effect.

Members are advised to take note of the above and ensure compliance.

The detailed order is available on SEBI website (<http://www.sebi.gov.in>). Further, the consolidated list of such entities is available on the Exchange website <http://www.nseindia.com> home page under “Domestic Investors – Regulatory – Regulatory Actions”.

In case of any further queries, members are requested to contact the following officials:

Ms. Samiksha Wadkar (Extn: 25413), Mr. Chirag Jain (Extn: 22480)

Direct No: 022-26598417/18

Fax: 022-26598195

For and on behalf of

National Stock Exchange of India Limited

Avishkar Naik

Vice President